<Suppliers Price>

Eltrombopag olamine

Names

[ CAS No. ]:
496775-62-3

[ Name ]:
Eltrombopag olamine

[Synonym ]:
Eltrombopag olamine
Revolade
Promacta
UNII-4U07F515LG
[1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-, compd. with 2-aminoethanol (1:2)
3'-{(2Z)-2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid - 2-aminoethanol (1:2)
Eltrombopag diethanolamine salt
Eltrombopag Impurity 1
Eltrombopag (Olamine)

Biological Activity

[Description]:

Eltrombopag is a thrombopoietin-receptor agonist used to treat low blood platelet counts with chronic immune thrombocytopenia.

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Thrombopoietin Receptor

Research Areas >> Cardiovascular Disease

[References]

[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.

[2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.

[3]. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36.

[4]. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41.

[5]. Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

[Related Small Molecules]

Lusutrombopag | avatrombopag | TPO agonist 1

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₉H₃₆N₆O₆

[ Molecular Weight ]:
564.633

[ Exact Mass ]:
564.269653

[ PSA ]:
209.05000

[ LogP ]:
3.12780

[ Storage condition ]:
-20℃

Related Compounds